Institut Curie - LIP - Lung Cancer

The Pre-clinical investigation laboratory at the Curie Institute (LIP) has 25 years experience in developing patient-derived PDXs of a wide range of cancers including breast, colon, lung, ovary, uveal melanoma, retinoblastoma, Head and Neck cancers.

The Pre-clinical investigation laboratory is developing the next generation of PDX models, from drug-resistant tumors, metastatic cancer to humanized models. LIP services includes:

• Preclinical pharmacology & pharmacodynamics of anti-cancer drugs
• Identification of predictive biomarkers of response and resistance to anti-cancer agents
• Collaboration with many national and European academics & pharmaceutical companies Read more

We have established a collection of heterotopic ovarian cancers PDXs.

The Pre-clinical investigation laboratory is a member of the EurOPDX Consortium. EurOPDX is supported by the European Union's Horizon 2020 research and innovation programme under the grant agreement No. 731105 EDIReX